UNIIQ

UNIIQ is an investment fund based in The Hague, Netherlands, with a focus on the proof-of-concept phase. Established in 2016, it manages a fund of €22 million aimed at supporting entrepreneurs in South Holland in bringing their unique innovations to market. UNIIQ provides essential start-up capital to help bridge the most critical phase of transforming ideas into promising businesses. By collaborating closely with knowledge institutions and incubators, UNIIQ actively aids entrepreneurs in their strategic development. The investments made by UNIIQ are utilized for validating innovations and business concepts, with the ultimate goal of facilitating the transition to further financing. The fund emphasizes a straightforward process with favorable conditions for entrepreneurs, ensuring they can effectively move forward with their projects.

Bart Hoenen

Investment Manager

Willem van Holthe

Investment Manager

Past deals in Rotterdam

Buddy Payment

Seed Round in 2019
Buddy Payment B.V., founded in 2018 and headquartered in Rotterdam, Netherlands, develops an innovative internet banking application called Buddy. This application assists users in managing their financial obligations by providing tools to send inquiries regarding bills, surcharges, or benefits. Buddy Payment focuses on debt prevention, offering insights into income and expenses while guiding users in managing their accounts. The application also provides helpful tips on saving money on purchases and fixed costs, empowering users to gain better control over their cash flow and payment management.

Captain AI

Seed Round in 2019
Captain AI B.V., founded in 2018 and based in Rotterdam, Netherlands, specializes in developing autonomous shipping solutions. The company employs high-fidelity simulation, sensors, and advanced deep learning techniques to create innovative software for the maritime industry. By utilizing a sophisticated simulator, Captain AI tests and validates its code, allowing for rapid iterations that enhance the development process. This approach not only facilitates the quicker implementation of autopilot systems for businesses requiring autonomous ships but also helps reduce emissions, fuel costs, and resource consumption.

Focus

Pre Seed Round in 2019
Focus is a Rotterdam-based legal tech startup founded in 2019. It specializes in developing an algorithm that ranks patents based on their technological importance, combining industry knowledge with econometric modeling.

Clockworks

Seed Round in 2018
Clockworks Data Innovation B.V., founded in 2017 and based in Rotterdam, the Netherlands, specializes in big data consultancy and custom data science solutions. The company focuses on developing predictive models and integrated software products to harness the power of big data. Its key applications include deepskye, which analyzes natural and built environments using satellite imagery, and a digitization solution that enables users to read water, gas, and electricity meters via their mobile phone's camera. Additionally, Clockworks provides predictive maintenance services that help users determine the remaining life of their assets, thereby optimizing maintenance efforts. By combining pattern recognition with human expertise, the company also offers process optimization solutions, enabling clients to derive actionable insights from their data.

Numeric Biotech

Seed Round in 2018
Numeric Biotech is a biotechnology company based in Rotterdam, the Netherlands. It specializes in developing compounds targeting cell senescence to treat and prevent age-related diseases, including cancer.

Sensius

Seed Round in 2017
Sensius is a medical device company based in Rotterdam, Netherlands, founded in 2015. It develops a thermotherapy (hyperthermia) system for head and neck cancer that combines proprietary thermal technology with interactive software and integrated microwave sources. The device is designed by clinicians to tailor treatments, using consumable collars to target the head and neck region. The technology aims to augment standard cancer therapies such as radiotherapy and chemotherapy by improving treatment outcomes and quality of life while reducing associated side effects. Sensius markets its system to oncology clinics and is pursuing CE and FDA clearance, with early interest from potential purchasers as regulatory milestones are approached.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.